全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Prognostic Clinico-Pathological Features of 99 Cases Advanced Non-Small Cell Lung Cancer—Egyptian National Cancer Institute

DOI: 10.4236/alc.2015.43005, PP. 29-36

Keywords: Non-Small Cell, Lung Cancer, Clinico-Pathological, Prognosis, NCI Egypt

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Worldwide, lung cancer is the most commonly diagnosed cancer and causes more deaths than any other cancer. In Egypt; it accounts for 7% of male cancer & 3% in females. It is considered to be 3rd most common cancer in Egyptian males & 6th most common of both sexes. Materials and Methods: A total of 99 advanced non-small cell lung cancer patients who underwent first line platinum containing chemotherapy in our institute were included in this study. All clinical and pathological data were collected from patient’s files retrospectively between 2012-2014. Results: All 99 cases were diagnosed at late stage IIIB-IV (59 cases were IIIB).The median age was 54 years (range: 30 - 70) with 53% of cases are ≥ 54 years. 71% were males with male: female ratio of 2.4:1. All male patients were chronic smokers. The most frequent symptom was coughing (68%). Most of the patients had primary lung cancer in the right lung (77%). The most common histological subtype was squamous cell carcinoma (35.4%) with 54 cases present with PS-I, the remain was PS-II. All cases received platinum containing chemotherapy. The majority of cases experienced a progressive disease 60.6%. The median progression free survival (PFS) was 6 months & median overall survival (OS) was 18 months. We found that PS, disease stage, pathological subtypes and response to treatment statistically affect both median OS & PFS. Age affects only OS. Conclusions: Our analysis suggests that some of clinico-pathological factors & response to first line platinum containing regimens affect both OS & PFS of advanced NSCLC. This may be beneficial as prognostic markers and further studies were needed to aid in identification and treatment of these patients.

References

[1]  World Health Organization Media Centre. Cancer. Fact Sheet No. 297.
http://www.who.int/mediacentre/factsheets/fs297/en/
[2]  Ibrahim, A.S., Khaled, H. M., Mikhail, N.N.H., Baraka, H. and Kamel, H. (2014) Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. Journal of Cancer Epidemiology, 2014, Article ID: 437971.
[3]  Rawat, J., Sindhwani, G., Gaur, D., Dua, R. and Saini, S. (2009) Clinico-Pathological Profile of Lung Cancer in Uttarakhand. Lung India, 26, 74-76.
http://dx.doi.org/10.4103/0970-2113.53229
[4]  Kumar, B.S., Abhijit, M., Debasis, D., Abinash, A., Ghoshal, A.G. and Kumar, D.S. (2011) Clinico-Pathological Profile of Lung Cancer in a Tertiary Medical Centre in India: Analysis of 266 Cases. Journal of Dentistry and Oral Hygiene, 3, 30-33.
[5]  de Mello, R.A., Marques, D.S., Medeiros, R. and Araujo, A.M. (2011) Epidermal Growth Factor Receptor and K-Ras in Non-Small Cell Lung Cancer-Molecular Pathways Involved and Targeted Therapies. World Journal of Clinical Oncology, 2, 367-76. [PMC free article] [PubMed]
http://dx.doi.org/10.5306/wjco.v2.i11.367
[6]  Dempke, W.C. (2015) Targeted Therapy for NSCLC—A Double-Edged Sword? Anticancer Research, 35, 2503-12.
[7]  Novaes, F.T., Cataneo, D.C., Ruiz Junior, R.L., Defaveri, J., Michelin, O.C. and Cataneo, A.J. (2008) Lung Cancer: Histology, Staging, Treatment and Survival. Jornal Brasileiro de Pneumologia, 34, 595-600.
http://dx.doi.org/10.1590/S1806-37132008000800009
[8]  Shimada, Y., Saji, H., Kato, Y., Kudo, Y., Maeda, J., Yoshida, K., et al. (2015) The Frequency and Prognostic Impact of Pathological Microscopic Vascular Invasion According to Tumor Size in Non-Small Cell Lung Cancer. Chest. Downloaded From:
http://journal.publications.chestnet.org
[9]  Freedman, L.S., Edwards, B.K., Ries, L.A. and Young, J.L. (2002) Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER.
[10]  Li, J., Wei, Z., Li, H., Dang, Q., Zhang, Z., Wang, L., et al. (2015) Clinico-Pathological Significance of Fibroblast Growth Factor 1 in Non-Small Cell Lung Cancer. Human Pathology, 46, 1821-1828.
[11]  Ramalingam, S., Pawlish, K., Gadgeel, S., Demers, R. and Kalemkerian, G.P. (1998) Lung Cancer in Young Patients: Analysis of a Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology, 16, 651-657.
[12]  Mauri, D., Pentheroudakis, G., Bafaloukos, D., Pectasides, D., Samantas, E., et al. (2006) Non-Small Cell Lung Cancer in the Young: Aretrospective Analysis of Diagnosis, Management and Outcome Data. Anticancer Research, 26, 3175-3181.
[13]  Yang, P., Bamlet, W.R., Ebbert, J.O., Taylor, W.R. and de Andrade, M. (2004) Glutathione Pathway Genes and Lung Cancer Risk in Young and Old Populations. Carcinogenesis, 25, 1935-1944.
http://dx.doi.org/10.1093/carcin/bgh203
[14]  Liam, C.K., Lim, K.H. and Wong, C.M. (2002) Non-Small Cell Lung Cancer in Very Young and Very Old Malaysian Patients. Chest, 121, 309-310.
http://dx.doi.org/10.1378/chest.121.1.309-a
[15]  Skarin, A.T., Herbst, R.S., Leong, T.L., Bailey, A. and Sugarbaker, D. (2001) Lung Cancer in Patients under Age 40. Lung Cancer, 32, 255-264.
http://dx.doi.org/10.1016/S0169-5002(00)00233-6
[16]  Radzikowska, E., Roszkowski, K. and Glaz, P. (2001) Lung Cancer in Patients under 50 Years Old. Lung Cancer, 33, 203-211.
http://dx.doi.org/10.1016/S0169-5002(01)00199-4
[17]  Capewell, S., Wathen, C.G., Sankaran, R. and Sudlow, M.F. (1992) Lung Cancer in Young Patients. Respiratory Medicine, 86, 499-502.
http://dx.doi.org/10.1016/S0954-6111(96)80010-2
[18]  Kreuzer, M., Kreienbrock, L., Gerken, M., Heinrich, J., Bruske-Hohlfeld, I., et al. (1998) Risk Factors for Lung Cancer in Young Adults. American Journal of Epidemiology, 147, 1028-1037.
http://dx.doi.org/10.1093/oxfordjournals.aje.a009396
[19]  Zhang, J., Chen, S.F., Zhen, Y., Xiang, J., Wu, C., et al. (2010) Multicenter Analysis of Lung Cancer Patients Younger than 45 Years in Shanghai. Cancer, 116, 3656-3662.
http://dx.doi.org/10.1002/cncr.25100
[20]  Cagle, P.T., Dacic, S. and Allen, T.C. (2011) Genomic Pathology: Challenges for Implementation. Archives of Pathology & Laboratory Medicine, 135, 967-968.
http://dx.doi.org/10.5858/2011-0199-EDI
[21]  Cagle, P.T. and Allen, T.C. (2012) Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future. Archives of Pathology & Laboratory Medicine, 136, 1482-1491.
http://dx.doi.org/10.5858/arpa.2012-0508-RA
[22]  Cagle, P.T. and Chirieac, L.R. (2012) Advances in Treatment of Lung Cancer with Targeted Therapy. Archives of Pathology & Laboratory Medicine, 136, 504-509.
http://dx.doi.org/10.5858/arpa.2011-0618-RA
[23]  Blot, W.J. and Fraumeni Jr., J.F. (1996) Cancers of the Lung and Pleura. In: Schottenfeld, D. and Fraumeni Jr., J.F., Eds., Cancer Epidemiology and Prevention, 2nd Edition, Oxford University Press, New York, 637-665.
[24]  US Surgeon General and Centers for Disease Control and Prevention (2004) The Health Consequences of Smoking. A Report of the Surgeon General.
http://www.cdc.gov/tobacco/sgr/sgr_2004/index.htm
[25]  Eberhardt, W.E., De Ruysscher, D., Weder, W., Le Péchoux, C., De Leyn, P., Hoffmann, H., et al. (2015) ESMO Consensus Guidelines: Locally-Advanced Stage III Non-Small-Cell Lung Cancer (NSCLC). Annals of Oncology, 26, 1573-1588.
http://dx.doi.org/10.1093/annonc/mdv187
[26]  Koumarianou, A., Fountzilas, G., Kosmidis, P., Klouvas, G., Samantas, E., Kalofonos, C., et al. (2009) Non-Small Cell Lung Cancer in the Elderly: Clinico-Pathologic, Management and Outcome Characteristics in Comparison to Younger Patients. Journal of Chemotherapy, 21, 573-583.
http://dx.doi.org/10.1179/joc.2009.21.5.573
[27]  Novaes, F.T., Cataneo, D.C., Ruiz Junior, R.L., Defaveri, J. and Michelin, O.C. (2008) Antonio José Maria Cataneo Lung Cancer: Histology, Staging, Treatment and Survival. Jornal Brasileiro de Pneumologia, 34, 595-600.
http://dx.doi.org/10.1590/S1806-37132008000800009
[28]  Bhaskarapillai, B., Kumar, S.S. and Balasubramanian, S. (2012) Lung Cancer in Malabar Cancer Center in Kerala—A Descriptive Analysis. Asian Pacific Journal of Cancer Prevention, 13, 4639-4643.
http://dx.doi.org/10.7314/APJCP.2012.13.9.4639
[29]  Qi, Y., Schild, S.E., Mandrekar, S.J., Tan, A.D., Krook, J.E., Rowland, K.M., et al. (2009) Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 4, 1075-1082.
http://dx.doi.org/10.1097/JTO.0b013e3181ae27f5
[30]  Ou, S.H., Ziogas, A. and Zell, J.A. (2010) A Comparison Study of Clinico-Pathologic Characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) Patients by Smoking Status. Journal of Thoracic Oncology, 5, 158-168.
http://dx.doi.org/10.1097/JTO.0b013e3181c8cc62
[31]  Kawaguchi, T., Takada, M., Kubo, A., Matsumura, A., Fukai, S., Tamura, A., et al. (2010) Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-Small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLC. Journal of Thoracic Oncology, 5, 620-630.
http://dx.doi.org/10.1097/JTO.0b013e3181d2dcd9
[32]  Schveigert, D., Cicenas, S., Bublevic, J., Askinis, R., Sapoka, V. and Didziapetriene, V. (2010) The Role of Genetic and Other Biomarkers in NSCLC Prognosis. Central European Journal of Medicine, 9, 382-390.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413